Skip to Content
COVID-19 Resources
Contact DCTD
Show menu
Search this site
Last Updated: 06/02/2021

2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the ASCO Annual Meeting External Link from June 4-8, 2021. The following tables include the oral and poster presentations containing DCTD staff co-authors.

Oral Sessions

Title Abstract
ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) +/- lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS External Link 7503
Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols External Link 10007
Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial External Link 10008
P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE) External Link 11503
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma External Link 11506

Poster Presentations

(P=DCTD Presenter; *Poster Discussion Session)

Title Abstract
NCI’s national treatment trial networks: Experience and adaptations during COVID-19 External Link 1562
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-MATCH (EAY131) subprotocol U External Link 3087
Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors External Link 3088
Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS) External Link
P: Larissa Korde, MD, MPH
Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS) External Link 6566
*National Cancer Institute (NCI) implementation of the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) broadening clinical trials eligibility criteria External Link
P: Andrea Denicoff, RN, MS, ANP
Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study External Link 8563
Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC) External Link 10037
Minding the gap: Gynecologic oncology practices differ by gender External Link 11011
*Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS) External Link
P: Abdul Rafeh Naqash, MD
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO) External Link TPS2676
S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma External Link TPS9585